Chinese hypertension guidelines revision committee. 2024 Chinese guidelines for prevention and treatment of hypertension. Chin J Hypertens. 2024;33:603–700. https://zhgxyzz.boyuancb.com/#/browse_details?year=2024&issue=7&issuecid=303191.

Liu J. Highlights of the 2018 Chinese hypertension guidelines. Clin Hypertens. 2020;26:8. https://doi.org/10.1186/s40885-020-00141-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu J, Li Y, Ge J, Yan X, Zhang H, Zheng X, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet. 2024;404:245–55.

Article  PubMed  Google Scholar 

He J, Ouyang N, Guo X, Sun G, Li Z, Mu J, et al. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial. Lancet. 2023;401:928–38.

Article  PubMed  Google Scholar 

Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385:1268–79.

Article  CAS  PubMed  Google Scholar 

The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Report on Cardiovascular Health and Diseases in China 2022: an Updated Summary. Biomed Environ Sci 2023;36:669–701.

CAS  PubMed  Google Scholar 

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127–e248. https://doi.org/10.1016/j.jacc.2017.11.006. Erratum in: J Am Coll Cardiol. 2018;71:2275–9.

Article  PubMed  Google Scholar 

Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874–2071. Erratum in: J Hypertens. 2024;42:194.

Article  CAS  PubMed  Google Scholar 

McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur Heart J. 2024; ehae178, https://doi.org/10.1093/eurheartj/ehae178.

Liu J, Liu J, Li Y, Zhang Y, on behalf of Chinese Hypertension League and Beijing Hypertension Association Cardiometabolic Medicine Committee. Chinese expert consensus on application of smart wearable devices in management of hypertension in young and middle-aged population. Chin J Hypertens. 2022;30:720–4.

Google Scholar 

Sun N, Huo Y, Huang J. The current status of heart rate in Chinese hypertensive patients. Chin J Hypertens. 2015;23:934–9.

Google Scholar 

Liu J, Chen L, Yuan H, Huang K, Li G, Sun N, et al. Survey on uric acid in Chinese subjects with essential hypertension (SUCCESS): a nationwide cross-sectional study. Ann Transl Med. 2021;9:27. https://doi.org/10.21037/atm-20-3458.

Article  PubMed  PubMed Central  Google Scholar 

Sheng Y, Li M, Xu M, Zhang Y, Xu J, Huang Y, et al. Left ventricular and atrial remodeling in hypertensive patients using thresholds from international guidelines and EMINCA data. Eur Heart J Cardiovasc Imaging. 2022;23:166–74.

Article  PubMed  Google Scholar 

Zhou D, Yan M, Cai A, Xie Q, Cheng Q, Tang S, et al. Prognostic implications of left ventricular hypertrophy defined by the thresholds from the international and Chinese guidelines. J Clin Hypertens. 2023;25:628–37.

Article  Google Scholar 

Xu A, Ma J, Guo X, Wang L, Wu J, Zhang J, et al. Association of a province-wide intervention with salt intake and hypertension in Shandong province, China, 2011-2016. JAMA Intern Med. 2020;180:877–86.

Article  PubMed  PubMed Central  Google Scholar 

Neal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, et al. Effect of salt substitution on cardiovascular events and death. N Engl J Med. 2021;385:1067–77.

Article  CAS  PubMed  Google Scholar 

Wang Y, Feng L, Zeng G, Zhu H, Sun J, Gao P, et al. Effects of cuisine-based Chinese heart-healthy diet in lowering blood pressure among adults in China: multicenter, single-blind, randomized, parallel controlled feeding trial. Circulation. 2022;146:303–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Q, Cui Y, Jin R, Lang H, Yu H, Sun F, et al. Enjoyment of spicy flavor enhances central salty-taste perception and reduces salt intake and blood pressure. Hypertension. 2017;70:1291–9.

Article  CAS  PubMed  Google Scholar 

Chinese Society of Cardiology of Chinese Medical Association, Cardiovascular Disease Prevention and Rehabilitation Committee of Chinese Association of Rehabilitation Medicine, Cardiovascular Disease Committee of Chinese Association of Gerontology and Geriatrics, Thrombosis Prevention and Treatment Committee of Chinese Medical Doctor Association. Chinese guideline on the primary prevention of cardiovascular diseases. Cardiol Discov. 2021;1:70–104.

Article  Google Scholar 

Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395:1444–51.

Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet. 2022;399:1401–10.

Article  CAS  PubMed  Google Scholar 

Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397:2476–86.

Article  CAS  PubMed  Google Scholar 

Lai X, Dong Z, Wu S, Zhou X, Zhang G, Xiong S, et al. Efficacy and safety of Chinese herbal medicine compared with losartan for mild essential hypertension: a randomized, multicenter, double-blind, noninferiority trial. Circ Cardiovasc Qual Outcomes. 2022;15:e007923.

Article  PubMed  Google Scholar 

Flachskampf FA, Gallasch J, Gefeller O, Gan J, Mao J, Pfahlberg AB, et al. Randomized trial of acupuncture to lower blood pressure. Circulation. 2007;115:3121–9.

Article  PubMed  Google Scholar 

Zhang DY, Cheng YB, Guo QH, Shan XL, Wei FF, Lu F, et al. Treatment of masked hypertension with a Chinese herbal formula: a randomized, placebo-controlled trial. Circulation. 2020;142:1821–30.

Article  CAS  PubMed  Google Scholar 

Kario K, Wang JG, Chia YC, Wang TD, Li Y, Siddique S, et al. The HOPE Asia network 2022 up-date consensus statement on morning hypertension management. J Clin Hypertens. 2022;24:1112–20.

Article  Google Scholar 

Liu J, Li Y, Zhang X, Bu P, Du X, Fang L, et al. Chinese Hypertension League expert consensus committee on the management of nocturnal hypertension. Management of nocturnal hypertension: An expert consensus document from Chinese Hypertension League. J Clin Hypertens. 2024;26:71–83. https://doi.org/10.1111/jch.14757.

Article  Google Scholar